Chemotherapy May Be Vital to Long-Term Immunotherapy Efficacy in Bladder Cancer – OncLive
OncLive |
Chemotherapy May Be Vital to Long-Term Immunotherapy Efficacy in Bladder Cancer
OncLive What patient population sees the greatest benefit from immunotherapy? At this point, patient selection is based on the approval or labeling indications of the drug, where the patient lies in the spectrum of disease, and if they have any alternative … Americas Cancer Immunotherapy Market 2018 expect Continuous Growth of CAGR at 10.1% Forecast 2023 |
